Investors

News Releases

Date Title  
Toggle Summary Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
MISSISSAUGA, Ontario , Jan. 11, 2017 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of
Toggle Summary Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
MISSISSAUGA, Ontario , Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational candidate,
Toggle Summary Aralez Provides Update On PBM Formulary Status For Yosprala
-Secures Formulary Status with Express Scripts Inc. for Yosprala ™ - MISSISSAUGA, Ontario , Jan. 9, 2017 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ( Aralez or the Company ) today announced that it has entered into a rebate agreement with Express Scripts Inc.
Toggle Summary Aralez Added To The NASDAQ Biotechnology Index
MISSISSAUGA, Ontario , Dec. 19, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ( Aralez or the Company ) today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective as of the opening of trading on Monday, December 19, 2016 .
Toggle Summary Aralez Announces Commercial Launch Of BLEXTEN™ In Canada
MISSISSAUGA, Ontario , Dec. 19, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ( Aralez or the Company ) today announced the commercial launch of BLEXTEN™ (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic
Toggle Summary Aralez Provides Update on PBM Formulary Status for Yosprala
-Secures Formulary Status with CVS Caremark for YOSPRALA ™ MISSISSAUGA, Ontario , Dec. 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced that it has entered into a rebate agreement with CaremarkPCS Health (also known as
Toggle Summary Aralez to Participate at Two Upcoming Healthcare Conferences
MISSISSAUGA, Ontario , Nov. 30, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that Adrian Adams , Chief Executive Officer, will participate in the following healthcare conferences: Guggenheim's One-on-One
Toggle Summary New Post-Hoc Analysis Supports YOSPRALA™ Efficacy And Safety In Previous Heart Attack Patients Who Need Daily Aspirin Therapy To Prevent A Second Cardiovascular Event
-Shows Significant Reduction in Gastrointestinal Side Effects with Use of Fixed-Dose Combination of Aspirin and Proton Pump Inhibitor- MISSISSAUGA, Ontario , Nov. 14, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced new data
Toggle Summary Aralez Reports Third Quarter 2016 Financial Results
-Completed Acquisitions of ZONTIVITY ® ; Toprol-XL ® and its Authorized Generic- -Received U.S. Food and Drug Administration Approval and Launched YOSPRALA™- -Provides Improved 2016 Full Year Guidance- MISSISSAUGA, Ontario , Nov. 7, 2016 /PRNewswire/ --   Aralez Pharmaceuticals Inc.
Toggle Summary Aralez to Present at the Jefferies London Healthcare Conference
MISSISSAUGA, Ontario , Nov. 2, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Jefferies London Healthcare Conference to be held November 16-17, 2016 .

Copyright West LLC. Minimum 15 minutes delayed.